# MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
Canonical URL: https://biopharmsignal.com/news/MGNX/macrogenics-to-receive-milestone-payment-from-sanofi-for-recent-tzieldr-approval
Ticker: MGNX
Company: MacroGenics
Source: MacroGenics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.macrogenics.com
## Summary

ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it will receive a $24.5 million regulatory milestone payment

## Article Body
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it will receive a $24.5 million regulatory milestone payment
## Recent Company News
- 2026-07-02 13:25 EST — [MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals](https://biopharmsignal.com/news/MGNX/macrogenics-completes-sale-of-gmp-manufacturing-operations-to-bora-pharmaceutica-b2889ad8) — Source: MacroGenics
- 2026-06-25 13:46 EST — [MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval](https://biopharmsignal.com/news/MGNX/macrogenics-to-receive-milestone-payment-from-sanofi-for-recent-tzieldr-approval) — Source: MacroGenics
- 2026-06-25 13:46 EST — [MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum](https://biopharmsignal.com/news/MGNX/macrogenics-to-participate-in-the-stifel-2026-virtual-targeted-oncology-forum) — Source: MacroGenics
- 2026-06-25 13:46 EST — [MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation](https://biopharmsignal.com/news/MGNX/macrogenics-reports-first-quarter-2026-financial-results-and-highlights-business-transformation) — Source: MacroGenics
- 2026-06-25 13:46 EST — [MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals](https://biopharmsignal.com/news/MGNX/macrogenics-to-sell-gmp-manufacturing-operations-to-bora-pharmaceuticals) — Source: MacroGenics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)